SciELO - Scientific Electronic Library Online

 
vol.37 issue1Gut microbiota in chronic kidney diseasePractical application of stereological methods in experimental kidney animal models author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995

Abstract

BUADES FUSTER, Juan Manuel; SANCHIS CORTES, Pilar; PERELLO BESTARD, Joan  and  GRASES FREIXEDAS, Félix. Plant phosphates, phytate and pathological calcifications in chronic kidney disease. Nefrología (Madr.) [online]. 2017, vol.37, n.1, pp.20-28. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2016.07.001.

Phytate, or myo-inositol 1,2,3,4,5,6-hexakis dihydrogen phosphate (InsP6), is a naturally occurring phosphorus compound that is present in many foods, mainly legumes, whole grains and nuts. Patients with chronic kidney disease (CKD) have cardiovascular disease mortality up to 30 times higher than the general population. Vascular calcifications (VCs) directly contribute to overall morbidity and mortality, especially in CKD. In part, this high mortality is due to elevated levels of phosphorus in the blood. Therefore, control of dietary phosphorus is essential. Dietary phosphorus can be classified according to its structure in organic phosphorus (plant and animal) and inorganic (preservatives and additives). Plant-phosphorus (legumes and nuts), mainly associated with InsP6, is less absorbable by the human gastrointestinal tract as the bioavailability of phosphorous from plant-derived foods is very low. Recent data indicate that restriction of foods containing plant phosphates may compromise the adequate supply of nutrients that have a beneficial effect in preventing cardiovascular events, such as InsP6 or fibre found in legumes and nuts. Experimental studies in animals and observational studies in humans suggest that InsP6 can prevent lithiasis and VCs and protect from osteoporosis. In conclusion, we need prospective studies to elucidate the potential benefits and risks of phytate (InsP6) through the diet and as an intravenous drug in patients on haemodialysis.

Keywords : Chronic kidney disease; Hyperphosphataemia; Phytate; Phytic acid; Vascular calcifications; Calciphylaxis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )